О.в. Забудський
Research Subjects
О.в. Забудський has a total of 3 co-authors. Here are the top co-authors by number of shared publications:
- Dariia Andreishyna
Shupyk National Healthcare University of Ukraine, Kyiv
1 shared publication - Karina Derba
Shupyk National Healthcare University of Ukraine, Kyiv
1 shared publication - Svitlana Zhuk
Shupyk National Healthcare University of Ukraine, Kyiv
1 shared publication
Latest Publications
- Open Access
- 30 September 2025
- Published by Professional Event, LLC in Reproductive health of woman
- No. 6,p. 27-32
Choice of therapy for aerobic vaginitis: a clinical and microbiological comparison
Aerobic vaginitis (AV) is an inflammatory disease of the vagina that occurs as a result of dysbiosis of the vaginal environment with a predominance of aerobic opportunistic microorganisms, such as Escherichia coli, Staphylococcus aureus, Streptococcus spp., etc. Frequent recurrence and insufficient diagnosis determine the relevance of research into effective methods of therapy for this disease.The objective: to compare the clinical and microbiological efficacy of two vaginal combination preparations in the treatment of AV in non-pregnant women.Materials and methods. The study included 80 non-pregnant women aged 18 to 45 years with a confirmed diagnosis of AV. The patients were randomized into two equal groups: the main group received medication Tergynan (ternidazole, neomycin sulfate, nystatin, prednisolone sodium metasulfobenzoate), and the comparison group received another combination preparation (ornidazole, miconazole, neomycin sulfate, prednisolone). Diagnostics included microscopy, bacteriological examination of vaginal discharge, gynecological examination, and a patient questionnaire. Treatment effectiveness was evaluated on the 11th and 30th days after therapy.Results. Patients in the main group experienced faster clinical symptom relief (1–2 days earlier) and the frequency of complete recovery immediately after the end of therapy was 85% versus 62% in the comparison group. After 30 days, recurrence occurred in only 9% of women who used Tergynan versus 36% in the comparison group.Conclusions. Tergynan demonstrated significantly higher clinical and microbiological efficacy in the treatment of AV, which justifies its advantages as the drug of choice in the case of this pathology.
- 30 September 2025
- Published by Professional Event, LLC in Reproductive health of woman
- No. 6,p. 27-32
Open AccessChoice of therapy for aerobic vaginitis: a clinical and microbiological comparison
Aerobic vaginitis (AV) is an inflammatory disease of the vagina that occurs as a result of dysbiosis of the vaginal environment with a predominance of aerobic opportunistic microorganisms, such as Escherichia coli, Staphylococcus aureus, Streptococcus spp., etc. Frequent recurrence and insufficient diagnosis determine the relevance of research into effective methods of therapy for this disease.The objective: to compare the clinical and microbiological efficacy of two vaginal combination preparations in the treatment of AV in non-pregnant women.Materials and methods. The study included 80 non-pregnant women aged 18 to 45 years with a confirmed diagnosis of AV. The patients were randomized into two equal groups: the main group received medication Tergynan (ternidazole, neomycin sulfate, nystatin, prednisolone sodium metasulfobenzoate), and the comparison group received another combination preparation (ornidazole, miconazole, neomycin sulfate, prednisolone). Diagnostics included microscopy, bacteriological examination of vaginal discharge, gynecological examination, and a patient questionnaire. Treatment effectiveness was evaluated on the 11th and 30th days after therapy.Results. Patients in the main group experienced faster clinical symptom relief (1–2 days earlier) and the frequency of complete recovery immediately after the end of therapy was 85% versus 62% in the comparison group. After 30 days, recurrence occurred in only 9% of women who used Tergynan versus 36% in the comparison group.Conclusions. Tergynan demonstrated significantly higher clinical and microbiological efficacy in the treatment of AV, which justifies its advantages as the drug of choice in the case of this pathology.